acrovestone: isolated from the stem bark of Acronychia pedunculata; RN given from CAS Index Guide (1982-1986) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
acrovestone : A polyphenol that is isolated from Acronychia pedunculata and exhibits moderate antioxidant and antityrosinase activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Acronychia | genus | [no description available] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
| Acronychia pedunculata | species | [no description available] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 159969 |
| CHEMBL ID | 488313 |
| CHEBI ID | 2440 |
| SCHEMBL ID | 1230905 |
| MeSH ID | M0170000 |
| Synonym |
|---|
| nsc-612789 |
| NSC612789 , |
| NCI60_004870 |
| 1-(3-{1-[3-acetyl-2,6-dihydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-methylbutyl}-2,4,6-trihydroxy-5-(3-methylbut-2-en-1-yl)phenyl)ethan-1-one |
| CHEBI:2440 , |
| C09916 |
| acrovestone |
| 24177-16-0 |
| ethanone, 1-(3-(1-(3-acetyl-2,6-dihydroxy-4-methoxy-5-(3-methyl-2-butenyl)phenyl)-3-methylbutyl)-2,4,6-trihydroxy-5-(3-methyl-2-butenyl)phenyl)- |
| CHEMBL488313 , |
| SCHEMBL1230905 |
| Q27105669 |
| DTXSID80946997 |
| 1-[3-{1-[3-acetyl-2,6-dihydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-methylbutyl}-2,4,6-trihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]ethan-1-one |
| bdbm50267248 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| antioxidant | A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. |
| EC 1.14.18.1 (tyrosinase) inhibitor | Any EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosinase (monophenol monooxygenase), EC 1.14.18.1, an enzyme that catalyses the oxidation of phenols (such as tyrosine) and is widespread in plants and animals. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| acetophenones | A class or aromatic ketone consisting of acetophenone, PhC(=O)CH3, and its substituted derivatives. |
| polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| olefinic compound | Any organic molecular entity that contains at least one C=C bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | IC50 (µMol) | 1.1000 | 0.0010 | 2.0308 | 10.0000 | AID1484243 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 2.5000 | 0.0001 | 1.6847 | 9.3200 | AID1484241; AID1484242 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1616504 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay | |||
| AID1484249 | Cytotoxicity against human neutrophils assessed as reduction in cell viability up to 10 uM up to 30 mins by light microscopic and trypan blue exclusion assay | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. |
| AID1484242 | Inhibition of 5-LO in human peripheral blood neutrophils using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins in presence of Ca2+ ionophore A23187 by RP-HPLC analysis | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. |
| AID1484243 | Inhibition of human A549 cell microsomal membrane-derived mPGES-1 assessed as reduction in conversion of PGH2 to PGE2 preincubated for 15 mins followed by PGH2 addition measured after 1 min by RP-HPLC analysis | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. |
| AID1484250 | Inhibition of human recombinant 5-LO expressed in Escherichia coli MV1190 assessed as residual activity at 10 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by RP-HPLC analysis relativ | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. |
| AID1616506 | Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay | |||
| AID1616505 | Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay | |||
| AID1484241 | Inhibition of human recombinant 5-LO expressed in Escherichia coli MV1190 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by RP-HPLC analysis | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. |
| AID1616507 | Antiproliferative activity against P-gp overexpressing human KBVIN cells assessed as reduction in cell viability after 72 hrs by SRB assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||